Companies /Healthcare
Arcus Biosciences Inc
NYSE: RCUS Biotechnology
$15.62
▼ $0.16 (−1.01%) today
Markets closed · 10:15pm ET

Arcus Biosciences (RCUS) Q3 2026 Earnings

Reported Nov 4, 2026, 4:08pm ET · SEC source
$-1.00
Miss −12.04%
EPS · est. $-0.89 GAAP
$9.0M
Beat +8.83%
Revenue · est. $8.3M
1 quarter
Consecutive EPS misses

How Did RCUS Stock React to Q3 2026 Earnings?

% change · around the report
−8%−4%0Nov 4Nov 5report 4:08pm ETearnings−4.8%−10.9%
−8%−4%0Nov 4Nov 5earnings−4.8%−10.9%
RCUS −10.9%S&P 500 −4.8%
−8%−4%0Nov 4Nov 5report 4:08pm ETearnings−6.8%−10.9%
−8%−4%0Nov 4Nov 5earnings−6.8%−10.9%
RCUS −10.9%NASDAQ −6.8%
−8%−4%0Nov 3Nov 12report 4:08pm ETearnings−1.4%−9.3%
−8%−4%0Nov 3Nov 12earnings−1.4%−9.3%
RCUS −9.3%S&P 500 −1.4%
−8%−4%0Nov 3Nov 12report 4:08pm ETearnings−0.7%−9.3%
−8%−4%0Nov 3Nov 12earnings−0.7%−9.3%
RCUS −9.3%NASDAQ −0.7%
−8.39%
Day of report
+3.34%
Next session
+0.45%
One week

Did RCUS Beat Earnings? Q3 2026 Results

No. Arcus Biosciences reported Q3 2026 earnings of $-1.00 a share on Nov 4, 2026, missing the $-0.89 consensus estimate by 12.0%. Revenue was $9.0M against a $8.3M estimate.

Arcus Biosciences delivered a split verdict in the third quarter of 2026, beating on revenue while falling short on the bottom line, as the wind-down of its Gilead collaboration continued to reshape the company's financial profile. Revenue came in at $9.00 million, clearing the $8.27 million consensus by 8.83%, though it still represented a sharp 65.4% decline from a year earlier as collaboration reimbursements fell to $12.00 million from $28.00 million. On a GAAP basis, earnings per share landed at a loss of $1.00, missing the $0.89 consensus loss estimate by 12.04%, with the net loss narrowing modestly to $128.00 million from $135.00 million as total operating expenses declined to $140.00 million. The quarter's real story, however, was casdatifan, the HIF-2α inhibitor that management is positioning as a backbone therapy across every line of kidney cancer treatment, with investors eyeing a market opportunity the company has characterized at $5 billion to $10 billion. For the full year, Arcus guides GAAP revenue of $70.00 million to $75.00 million, and with $694.00 million in cash supplemented by $288.00 million in October equity proceeds, management projects a funding runway into 2029.

Key Takeaways
  • Revenue decline driven by lower Gilead Collaboration revenue as activities wind down or reach completion
  • Revenue decline partially offset by higher Taiho Collaboration Agreement revenue
  • R&D expenses fell on wind-down of domvanalimab Phase 2/3 studies and completed PRISM-1 enrollment
  • R&D savings partially offset by increased casdatifan Phase 3 activity
  • Partnership reimbursements decreased ($12M vs $28M) due to shift toward fully self-funded programs
  • G&A decreased due to streamlining initiatives

“In October, we showed for the first time that robust and durable HIF-2α inhibition from casdatifan can address the needs of patients at every line of kidney cancer therapy: rapid and sustained disease control in the first line, durable benefit and potential survival advantage in the second line, even after a prior TKI-inclusive therapy, and nearly three years of median overall survival in late-line patients who had exhausted multiple therapies.”

Arcus Biosciences CEO, on the earnings call

What Is Arcus Biosciences's Outlook?

Revenue and spending: - Arcus expects full-year 2026 GAAP revenue of $70 million to $75 million. - R&D expenses are expected to remain relatively consistent in the near term, as casdatifan and immunology investment offsets declines in other programs. - Cash of $694 million at quarter end plus $288 million in gross October equity proceeds is expected to fund operations into 2029. Near-term milestones: - PEAK-1 enrollment is expected to complete in two to three months. - PEAK-20 is expected to initiate in Q4 2026. - Bispecific combination cohorts and a randomized casdatifan-plus-tivozanib late-line cohort are expected to begin by year-end. - The PRISM-1 interim analysis is expected in Q4 2026. 2027 milestones: - A first-line anti-PD-1 plus axitinib cohort is planned for 1H 2027 to support PEAK-21. - More mature ARC-20 PFS and OS data are expected. - Immunology candidates are expected to enter the clinic or reach IND-ready status.

RCUS YoY Financials

Q3 2026 vs Q3 2025 · SEC filings Q3 2025 Q3 2026
$-150,000,000$-100,000,000$-50,000,000$0$26.0M$9.0MRevenue$-121,577,726$-131,000,000Operating Income$-121,684,571$-128,000,000Net Income
$-150,000,000$-100,000,000$-50,000,000$0RevenueOperating IncomeNet Income
RCUS income statement, Q3 2026 versus Q3 2025
Metric Q3 2026 Q3 2025 Year over year
Revenue $9.0M $26.0M −65.4%
Operating Income −$131.0M −$121.6M +7.7%
Net Income −$128.0M −$121.7M +5.2%

RCUS Revenue by Segment

License and Development Service$8.0M−60.0%
Other Collaboration$1.0M−83.3%

Figures from SEC filings and company reports. Not investment advice.